To view the PDF documents you will need the Acrobat Reader. Please click here to download the free Adobe Acrobat Reader software.
2011 | |
|---|---|
September 29, 2011 | Phase III Study of Bayer’s Rivaroxaban in Patients with Acute Coronary Syndrome Meets Primary Efficacy Endpoint |
September 6, 2011 | Bayer AG: FDA has published documents for discussion at the Advisory Committee on the new drug application for Rivaroxaban |
2010 | |
|---|---|
October 31, 2010 | Bayer AG: Phase III ROCKET AF Study of Rivaroxaban meets its primary efficacy endpoint with Comparable Safety vs. Warfarin |
August 4, 2010 | Bayer AG: Rivaroxaban Meets Primary Endpoint in Long-Term Phase III EINSTEIN-DVT Study |
2009 | |
|---|---|
September 15, 2009 | Dr. Marijn E. Dekkers to be new CEO of Bayer from October 1, 2010 |
2008 | |
|---|---|
March 3, 2008 | Bayer AG: Court Decides against the Company’s Yasmin® Patent |
2007 | |
|---|---|
April 26, 2007 | Bayer exceeds consensus estimates for Q1 2007
|
Older ad-hoc publications can be found in the Archive.
You are leaving the Bayer AG website.
Bayer AG is not responsible for the information on the website to which you are linking.
collect